PD0332991
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for PD0332991, covering 2015-05-21 to 2020-06-05. Get the full timeline:
Most recent: Clinical Trial Update: A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression [Phase 2]